Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 386 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Allergies Clear all
Completed Phase 1 Interventional

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 23, 2026, 6:49 AM EDT
Recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

NCT07456033
View directory record Official record
Conditions
Asthma
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Little Rock, Arkansas • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 6:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

NCT02300363
View directory record Official record
Conditions
Healthy
Interventions
Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

NCT01156844
View directory record Official record
Conditions
Persistent Asthma
Interventions
Indacaterol, Placebo to Indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
21
States / cities
Anniston, Alabama • Cypress, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 23, 2026, 6:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acoustic Waveform Respiratory Evaluation

NCT06512064
View directory record Official record
Conditions
Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
Interventions
AWARE
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917111
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Nasal CO2, Inactive Placebo Gas
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

NCT02300350
View directory record Official record
Conditions
Healthy
Interventions
Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 23, 2026, 6:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT04210843
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

NCT03364608
View directory record Official record
Conditions
Asthma
Interventions
AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

NCT06686797
View directory record Official record
Conditions
Healthy
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

NCT00697710
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
50 mg S-777469, 200 mg S-777469, 800 mg S-777469, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

NCT04823130
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab (SAR231893)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Albuterol Spiromax® in Subjects With Asthma

NCT01698320
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 23, 2026, 6:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

NCT06119529
View directory record Official record
Conditions
Healthy, Atopic Dermatitis
Interventions
LY3872386, Prednisone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 6:49 AM EDT
Withdrawn Phase 2 Interventional

A Study of RO5036505 in Patients With Moderate to Severe Asthma

NCT00967590
View directory record Official record
Conditions
Asthma
Interventions
RO5036505, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis
Interventions
Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 3 Interventional

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

NCT00393952
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

NCT03290248
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
Interventions
B244 suspension, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 23, 2026, 6:49 AM EDT
Completed Phase 3 Interventional

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

NCT02492321
View directory record Official record
Conditions
Allergic Conjunctivitis (AC)
Interventions
EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
11
States / cities
Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 23, 2026, 6:49 AM EDT
Withdrawn Not applicable Interventional

LEGION™ Revision Metal Hypersensitivity Study

NCT02412813
View directory record Official record
Conditions
Total Knee Replacement Revision
Interventions
LEGION OXINIUM, LEGION Cobalt Chrome
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Egg Harbor, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 23, 2026, 6:49 AM EDT